Q2 2025 Taysha Gene Therapies Inc Earnings Call Transcript
Key Points
- Taysha Gene Therapies Inc (TSHA) has obtained alignment with the FDA and Health Canada to proceed with initiating their REVEAL pivotal trial for TSHA-102, indicating strong regulatory progress.
- The company reported positive clinical data supporting the therapeutic potential of TSHA-102, with all 10 patients in Part A of the REVEAL trials gaining or regaining developmental milestones.
- TSHA-102 is designed to target the genetic root cause of Rett syndrome, leveraging a clinically proven AAV9 vector and a minimally invasive lumbar intrathecal injection method.
- The company completed a public follow-on offering, resulting in total gross proceeds of $230 million, extending their cash runway into 2028.
- Taysha Gene Therapies Inc (TSHA) has a defined path to registration for TSHA-102, with a pivotal trial underway and a strengthened balance sheet.
- The company reported a net loss of $26.9 million for the three months ended June 30, 2025, compared to a net loss of $20.9 million for the same period in 2024.
- General and administrative expenses increased to $8.6 million for the three months ended June 30, 2025, primarily due to higher legal and professional fees.
- There are no currently approved therapies that treat the underlying genetic root cause of Rett syndrome, highlighting the urgency and challenge of developing effective treatments.
- The company faces risks and uncertainties that may cause actual results to differ materially from forward-looking statements, as noted in their SEC filings.
- The pivotal trial design relies on a novel regulatory pathway, which may present challenges in terms of regulatory approval and market acceptance.
Ladies and gentlemen, good morning, and welcome to Taysha Gene Therapies second quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Hayleigh Collins, Director, Head of Corporate Communications. Please go ahead.
Thank you. Good morning, and welcome to our second quarter 2025 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the second quarter ended June 30, 2025. A copy of this press release is available on the companyâs website and through our SEC filings.
Joining me on todayâs call are Sean Nolan, Tayshaâs Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; Kamran Alam, Chief Financial Officer and Dr. Elsa Rossignol, Director of the Integrated Rett Syndrome Clinic at Sainte-Justine in Montreal and Principal Investigator of the VEAL
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
